Technical description
Sparsentan is a biphenyl that is 1,1′-biphenyl substituted by (4,5-dimethyl-1,2-oxazol-3-yl)aminosulfonyl, ethoxymethyl, and (2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl groups at positions 2, 2′ and 4′, respectively. It is a dual antagonist of endothelin and angiotensin II receptors approved for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. It has a role as an antihypertensive agent, an endothelin A receptor antagonist, an angiotensin receptor antagonist and a nephroprotective agent. It is a member of biphenyls, a sulfonamide, an azaspiro compound, a member of isoxazoles and a benzyl ether.
